A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients

Jean-Eric Tarride1 McMaster Chair in Health Technology Management, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;2 Center for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton ON, Canada;3 Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe’s, St Joseph’s Healthcare Hamilton, Hamilton, ON, CanadaCorrespondence[email protected]

Trinh Luong4 Edwards Lifesciences (Canada) Inc ., Mississauga, ON, Canada

Gordon Goodall5 Edwards Lifesciences SA , Nyon, Switzerland

Natasha Burke3 Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe’s, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada

Gordon Blackhouse2 Center for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton ON, Canada;3 Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe’s, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada

A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date